The Medical Research Council has announced a £50 million investment in a new Centre of Research Excellence aimed at improving understanding and treatment of mitochondrial diseases, a group of genetic disorders that affect around one in 5,000 people. The programme is designed to bring together researchers across disciplines to define how mutations in mitochondrial DNA cause disease and then translate that knowledge into therapies.
Why the new centre matters for patients
The MRC said there is currently no cure for mitochondrial diseases, leaving patients and families with significant unmet medical needs. The condition can cause severe disability, progressive decline and premature death. The council also said mitochondrial DNA mutations are increasingly linked to neurodegeneration, metabolic disease, cardiovascular failure and age-related deterioration.
According to the MRC, the new centre will use emerging technologies to engineer the mitochondrial genome and create advanced models of pathogenic mtDNA mutations. The goal is to build the scientific foundations for new therapeutic strategies and improve prevention, detection and treatment. The announcement was published by UK Research and Innovation on 5 August 2026.
A UK-led effort with international partners
The centre will be led by the University of Cambridge and will partner with the University of Birmingham, The University of Manchester, Heidelberg University, the University of Queensland and the Imagine Institute in Paris. It will also work with charities including the Lily Foundation and industry partners worldwide.
Professor Michal Minczuk of the University of Cambridge, the project lead, said the centre will provide pioneering approaches to understanding and treating diseases caused by mutations in the mitochondrial genome and aims to position the UK as a global leader in mitochondrial genome therapeutics. Dr Ceri Williams, Executive Director of Challenge Led Themes at MRC, said the initiative builds on the UK’s previous leadership in mitochondrial science, including mitochondrial replacement therapy.
Long-term research platform built around unmet need
The MRC framed the investment as a long-term research platform rather than a short-term project, with the intention of developing the expertise and infrastructure needed to support future treatments. Liz Curtis, Chief Executive Officer and founder of the Lily Foundation, said the charity is proud to be a named partner and that embedding patient perspectives from the outset will help ensure research priorities reflect the needs of families affected by mitochondrial disease.
For UK medical research, the funding underlines growing interest in rare genetic disease biology and the translation of basic science into clinical applications. If the programme delivers on its aims, it could help move mitochondrial medicine closer to practical therapies for conditions that currently have no cure.
Photo source: AI-generated or edited image
